CUE Logo

Cue Biopharma, Inc. (CUE) 

NASDAQ
Market Cap
$67.78M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
349 of 774
Rank in Industry
197 of 432

Largest Insider Buys in Sector

CUE Stock Price History Chart

CUE Stock Performance

About Cue Biopharma, Inc.

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; …

Insider Activity of Cue Biopharma, Inc.

Over the last 12 months, insiders at Cue Biopharma, Inc. have bought $0 and sold $0 worth of Cue Biopharma, Inc. stock.

On average, over the past 5 years, insiders at Cue Biopharma, Inc. have bought $1.2M and sold $1.76M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 4,000 shares for transaction amount of $11,040 was made by Suri Anish (PRESIDENT AND CSO) on 2023‑08‑25.

List of Insider Buy and Sell Transactions, Cue Biopharma, Inc.

2023-08-25PurchasePRESIDENT AND CSO
4,000
0.0088%
$2.76$11,040-26.16%
2023-08-14PurchaseCHIEF EXECUTIVE OFFICER
3,000
0.0065%
$2.86$8,580-31.51%
2023-03-23Saledirector
9,325
0.0208%
$3.28$30,586-14.55%
2022-05-27Purchase
28,000
0.0769%
$3.75$105,000-19.17%
2022-05-23Purchase
55,000
0.1455%
$3.34$183,700-12.61%
2022-03-31Purchase
735,000
2.0277%
$4.76$3.5M-36.07%
2021-11-16Saledirector
1,361
0.0046%
$18.02$24,525-77.86%
2021-11-15SalePresident and CSO
8,000
0.0257%
$18.05$144,400-78.74%
2021-11-15Saledirector
18,815
0.0599%
$17.92$337,165-78.74%
2021-11-11SalePresident and CSO
20,000
0.0634%
$15.07$301,354-74.37%
2021-10-01SaleCHIEF FINANCIAL OFFICER
1,251
0.0039%
$14.21$17,783-66.60%
2021-09-24PurchaseCHIEF EXECUTIVE OFFICER
3,400
0.011%
$14.72$50,051-65.45%
2021-09-23SalePRESIDENT AND CSO
20,000
0.0648%
$15.23$304,646-66.40%
2021-03-16SaleChief Medical Officer
439
0.0015%
$15.09$6,626-19.03%
2021-03-15SaleChief Medical Officer
13,000
0.0427%
$15.10$196,269-20.52%
2021-02-17SaleChief Medical Officer
4,274
0.0142%
$15.05$64,345-17.94%
2021-02-16SaleChief Medical Officer
16,000
0.0525%
$15.15$242,422-19.24%
2021-01-20SaleChief Medical Officer
2,720
0.0093%
$15.07$40,980-13.79%
2021-01-20PurchaseChief Medical Officer
5,440
0.0187%
$15.07$81,959-13.79%
2020-11-24Purchasedirector
13,096
0.0466%
$12.64$165,552+4.77%

Insider Historical Profitability

31.86%
Fletcher Aaron G.L.
940000
1.4838%
$1.0740<0.0001%
Gray Camerondirector
677500
1.0695%
$1.0720<0.0001%
Suri AnishPRESIDENT AND CSO
135638
0.2141%
$1.0726+73.75%
PASSERI DANIEL RCHIEF EXECUTIVE OFFICER
134578
0.2124%
$1.0760+4.56%
DIGIANDOMENICO ANTHONYdirector
57000
0.09%
$1.0750+68.36%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bleichroeder Lp$5.21M5.662.76M+56.98%+$1.89M1.36
Slate Path Capital LP$4.54M4.942.4M0%+$00.09
The Vanguard Group$4.32M4.692.28M+7.05%+$284,363.72<0.0001
BlackRock$4.24M4.612.24M-4.05%-$178,911.15<0.0001
Geode Capital Management$1.59M1.72838,531+3.1%+$47,721.55<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.